Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 217 institutions reported holding it in 13F filings for Q3 2026, worth $3.79B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$3.42B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $1.82M in total
6
13F holdersQ3 2026, +7 vs. previous quarter
217
13F valueReported value at the end of Q3 2026
$3.79B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$103.7M
No comparable prior period
Free cash flow, FY2025
-$70.5M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
10.3M
Shares sold short
Change
+962.4K
+10.3% vs. previous
Days to cover
5.69
At average daily volume

Superinvestors holding ELVN, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding ELVN at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Enliven Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 19, 2026 (view filing)5:07 PM ETNov 172 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$46.84−$234.2K−16.7%25.0K after2 lots10b5-1
Oct 21, 2026 (view filing)5:53 PM ETOct 192 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$38.48−$231.5K−13.7%38.0K after10b5-1
Oct 21, 2026 (view filing)5:51 PM ETOct 192 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$38.47−$192.3K−16.7%25.0K after10b5-1
Oct 5, 2026 (view filing)4:57 PM ETOct 14 daysGarland J. ScottDirectorSSale−13.0K$46.67−$606.7K−100.0%0 after
Sep 21, 2026 (view filing)5:23 PM ETSep 174 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$50.35−$303.0K−13.7%38.0K after3 lots10b5-1
Sep 21, 2026 (view filing)5:22 PM ETSep 174 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$50.35−$251.8K−16.7%25.0K after3 lots10b5-1
Aug 19, 2026 (view filing)4:17 PM ETAug 172 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$58.58−$352.6K−13.1%40.0K after2 lots10b5-1
Aug 19, 2026 (view filing)4:16 PM ETAug 172 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$58.59−$292.9K−16.7%25.0K after2 lots10b5-1
Aug 6, 2026 (view filing)8:18 PM ETAug 42 daysDerynck Mika KDirectorSSale−158.8K$60.21−$9.56M−100.0%0 after10b5-1
Jul 21, 2026 (view filing)5:24 PM ETJul 174 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$52.64−$316.8K−11.6%46.1K after5 lots10b5-1

Top 10 13F holders, Q3 2026

See all 217 holders

The largest institutional positions in Enliven Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding ELVN in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC10,827,727$496.3M0.02%+802,710+8.0%Added
OrbiMed Advisors LLC6,776,632$310.6M5.70%00.0%Unchanged
Polar Capital Holdings Plc6,425,271$294.5M0.82%−5,365−0.1%Reduced
BlackRock, Inc.5,711,966$261.8M0.00%+1,352,262+31.0%Added
Commodore Capital LP3,275,000$150.1M11.63%00.0%Unchanged
Vestal Point Capital, LP3,225,000$147.8M3.82%−775,000−19.4%Reduced
Vanguard Capital Management LLC2,893,109$132.6M0.00%+324,107+12.6%Added
Price T Rowe Associates Inc2,350,207$107.7M0.01%−553,700−19.1%Reduced
Fairmount Funds Management LLC1,855,644$85.1M5.33%00.0%Unchanged
Geode Capital Management, LLC1,708,920$78.4M0.00%+301,718+21.4%Added

Holders of 5% or more of ELVN

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Enliven Therapeutics, Inc..

Largest holders of ELVN from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A15.00%10.7M shares+1.70 ppfrom 13.30%Feb 8, 20218 filingsAug 6, 2026SEC
OrbiMed Advisors LLC13D/A9.50%6.77M shares−1.43 ppfrom 10.93%Feb 28, 20236 filingsJun 24, 2026SEC
Polar Capital Holdings Plc13G/A8.46%5.06M shares0.00 ppfrom 8.46%Nov 13, 20246 filingsJun 22, 2026SEC
Commodore Capital LP13G/A7.70%4.80M shares−2.20 ppfrom 9.90%Oct 24, 20229 filingsMay 15, 2026SEC
BlackRock, Inc.13G/A7.10%5.21M shares+2.00 ppfrom 5.10%Oct 24, 20244 filingsOct 27, 2026SEC